Clinical evaluation
Patients with colorectal cancer present in three ways:
Outpatients with suspicious symptoms and signs
Asymptomatic individuals discovered by routine screening of average and high-risk subjects
Rarely, emergency admission with intestinal obstruction, peritonitis or bleeding.
All patients, regardless of age, presenting with symptoms associated with colorectal cancer, should undergo a prompt tailored evaluation for both gastrointestinal and non-gastrointestinal causes.[41]National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: colorectal cancer screening [internet publication].
https://www.nccn.org/professionals/physician_gls/default.aspx
Abdominal pain, change in bowel habit, rectal bleeding, or anaemia are the most common presenting symptoms. Abdominal pain in isolation, rectal bleeding associated with anal symptoms, and change in bowel habit with harder stools, have a low predictive value for colorectal cancer. US and UK guidelines report risk thresholds for testing among low- to average-risk symptomatic populations.[41]National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: colorectal cancer screening [internet publication].
https://www.nccn.org/professionals/physician_gls/default.aspx
[110]Rex DK, Boland CR, Dominitz JA, et al. Colorectal cancer screening: recommendations for physicians and patients from the U.S. Multi-Society Task Force on Colorectal Cancer. Am J Gastroenterol. 2017 Jun 6;112(7):1016-30.
https://journals.lww.com/ajg/fulltext/2017/07000/Colorectal_Cancer_Screening__Recommendations_for.13.aspx
http://www.ncbi.nlm.nih.gov/pubmed/28555630?tool=bestpractice.com
[111]National Institute for Health and Care Excellence. Suspected cancer: recognition and referral. Aug 2023 [internet publication].
https://www.nice.org.uk/guidance/ng12
Left-sided colorectal cancer can present with a change in bowel habit due to a progressive narrowing of the bowel lumen, typically presenting with diarrhoea, a change in stool form (small calibre or ribbon-like stools) and, eventually, intestinal obstruction. However, the above symptoms are non-specific and can occur in other gastrointestinal conditions.
Between 6% and 10% of patients with iron-deficiency anaemia will be found to have colorectal cancer, most commonly on the right side of the colon.[3]Eng C, Yoshino T, Ruíz-García E, et al. Colorectal cancer. Lancet. 2024 Jul 20;404(10449):294-310.
http://www.ncbi.nlm.nih.gov/pubmed/38909621?tool=bestpractice.com
[112]Rockey DC, Cello JP. Evaluation of the gastrointestinal tract in patients with iron-deficiency anemia. N Engl J Med. 1993 Dec 2;329(23):1691-5.
https://www.nejm.org/doi/full/10.1056/NEJM199312023292303
http://www.ncbi.nlm.nih.gov/pubmed/8179652?tool=bestpractice.com
[113]Raje D, Mukhtar H, Oshowo A, et al. What proportion of patients referred to secondary care with iron deficiency anemia have colon cancer? Dis Colon Rectum. 2007 Aug;50(8):1211-4.
http://www.ncbi.nlm.nih.gov/pubmed/17587088?tool=bestpractice.com
Signs and symptoms of advanced disease
Abdominal distension, weight loss, and vomiting are the less common symptoms and may indicate advanced disease.[3]Eng C, Yoshino T, Ruíz-García E, et al. Colorectal cancer. Lancet. 2024 Jul 20;404(10449):294-310.
http://www.ncbi.nlm.nih.gov/pubmed/38909621?tool=bestpractice.com
Rectal pain may indicate a bulky tumour with local invasion in the pelvis. Tenesmus is frequent with rectal cancers. However, physical examination is frequently normal (other than in emergency cases) and should always include a digital rectal examination to check for a palpable lesion. In advanced disease, there may be a palpable abdominal mass or liver enlargement due to metastases.
Endoscopy
Complete examination of the colon is indicated in patients with suspected colorectal cancer.[114]Atkin W, Dadswell E, Wooldrage K, et al; SIGGAR Investigators. Computed tomographic colonography versus colonoscopy for investigation of patients with symptoms suggestive of colorectal cancer (SIGGAR): a multicentre randomised trial. Lancet. 2013 Apr 6;381(9873):1194-202.
http://www.ncbi.nlm.nih.gov/pubmed/23414650?tool=bestpractice.com
Colonoscopy
The preferred investigation, providing there is no clinical evidence of impending intestinal obstruction that would contraindicate administration of bowel preparation and insufflation of the colon.[3]Eng C, Yoshino T, Ruíz-García E, et al. Colorectal cancer. Lancet. 2024 Jul 20;404(10449):294-310.
http://www.ncbi.nlm.nih.gov/pubmed/38909621?tool=bestpractice.com
[115]Vogel JD, Felder SI, Bhama AR, et al. The American Society of Colon and Rectal Surgeons clinical practice guidelines for the management of colon cancer. Dis Colon Rectum. 2022 Feb 1;65(2):148-77.
https://journals.lww.com/dcrjournal/Fulltext/2022/02000/The_American_Society_of_Colon_and_Rectal_Surgeons.7.aspx
http://www.ncbi.nlm.nih.gov/pubmed/34775402?tool=bestpractice.com
It is the most sensitive diagnostic test for colorectal cancer and allows for biopsy of suspicious lesions and removal of incidental polyps.[3]Eng C, Yoshino T, Ruíz-García E, et al. Colorectal cancer. Lancet. 2024 Jul 20;404(10449):294-310.
http://www.ncbi.nlm.nih.gov/pubmed/38909621?tool=bestpractice.com
Colonoscopy is highly operator dependent
Completion rates (i.e., scope passed to the cecum) vary substantially, and a rate of 90% is considered acceptable. Many individuals achieve rates of 98%. Incomplete colonoscopy contributes to a miss rate of 2%, and poor bowel preparation contributes to a miss rate of 6%.[116]Bressler B, Paszat LF, Chen Z, et al. Rates of new or missed colorectal cancers after colonoscopy and their risk factors: a population-based analysis. Gastroenterology. 2007 Jan;132(1):96-102.
http://www.ncbi.nlm.nih.gov/pubmed/17241863?tool=bestpractice.com
Other procedural risks are related to sedation and colonic perforation (up to 0.12%).[117]Lieberman DA, Weiss DG, Bond JH, et al; Veterans Affairs Cooperative Study Group 380. Use of colonoscopy to screen asymptomatic adults for colorectal cancer. N Engl J Med. 2000 Jul 20;343(3):162-8.
https://www.nejm.org/doi/full/10.1056/NEJM200007203430301
http://www.ncbi.nlm.nih.gov/pubmed/10900274?tool=bestpractice.com
[118]Luning T, Keemers-Gels M, Barendregt W, et al. Colonoscopic perforations: a review of 30,366 patients. Surg Endosc. 2007 Jun;21(6):994-7.
http://www.ncbi.nlm.nih.gov/pubmed/17453289?tool=bestpractice.com
Alternative procedures
A flexible sigmoidoscopy may be appropriate in a low-risk patient, such as a patient younger than 50 years with an isolated rectal bleed. If a cancer is detected at flexible sigmoidoscopy, it is important that complete visualisation of the whole colon is achieved either pre- or postoperatively because synchronous cancers occur in around 5% of patients.[119]Holme Ø, Bretthauer M, Fretheim A, et al. Flexible sigmoidoscopy versus faecal occult blood testing for colorectal cancer screening in asymptomatic individuals. Cochrane Database Syst Rev. 2013 Oct 1;(9):CD009259.
https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009259.pub2/full
http://www.ncbi.nlm.nih.gov/pubmed/24085634?tool=bestpractice.com
Flexible sigmoidoscopy screening effectively reduced distal colorectal cancer incidence and mortality, compared with no screening, in one systematic review and meta-analysis[120]Zhang C, Liu L, Li J, et al. Effect of flexible sigmoidoscopy-based screening on colorectal cancer incidence and mortality: an updated systematic review and meta-analysis of randomized controlled trials. Expert Rev Anticancer Ther. 2023 Jul-Dec;23(11):1217-27.
http://www.ncbi.nlm.nih.gov/pubmed/37542427?tool=bestpractice.com
However, alone, it is not considered adequate screening for colorectal cancer.
Double-contrast barium enema is safe and well tolerated, and does not require intravenous sedation. However, patients in comparative studies preferred colonoscopy or computed tomography (CT) colonography to double-contrast barium enema for visualisation of the colon.[121]Gluecker TM, Johnson CD, Harmsen WS, et al. Colorectal cancer screening with CT colonography, colonoscopy, and double-contrast barium enema examination: prospective assessment of patient perceptions and preferences. Radiology. 2003 May;227(2):378-84.
http://www.ncbi.nlm.nih.gov/pubmed/12732696?tool=bestpractice.com
[122]Bosworth HB, Rockey DC, Paulson EK, et al. Prospective comparison of patient experience with colon imaging tests. Am J Med. 2006 Sep;119(9):791-9.
http://www.ncbi.nlm.nih.gov/pubmed/16945615?tool=bestpractice.com
[123]Halligan S, Wooldrage K, Dadswell E, et al; SIGGAR investigators. Computed tomographic colonography versus barium enema for diagnosis of colorectal cancer or large polyps in symptomatic patients (SIGGAR): a multicentre randomised trial. Lancet. 2013 Apr 6;381(9873):1185-93.
http://www.ncbi.nlm.nih.gov/pubmed/23414648?tool=bestpractice.com
[124]von Wagner C, Smith S, Halligan S, et al. Patient acceptability of CT colonography compared with double contrast barium enema: results from a multicentre randomised controlled trial of symptomatic patients. Eur Radiol. 2011 May 31;21(10):2046-55.
http://www.ncbi.nlm.nih.gov/pubmed/21626363?tool=bestpractice.com
[125]Rex DK, Rahmani EY, Haseman JH, et al. Relative sensitivity of colonoscopy and barium enema for detection of colorectal cancer in clinical practice. Gastroenterology. 1997 Jan;112(1):17-23.
http://www.ncbi.nlm.nih.gov/pubmed/8978337?tool=bestpractice.com
Double-contrast barium enema or CT colonography may be considered for patients who are unwilling to undergo colonoscopy, who are not suitable candidates for colonoscopy, or for whom colonoscopy is contraindicated.
Imaging studies
CT colonography (virtual colonoscopy) provides an endoluminal view of the colon similar to traditional colonoscopy. It has equal sensitivity to conventional colonoscopy for detection of colorectal cancer, and does not require sedation, but has less specificity.[114]Atkin W, Dadswell E, Wooldrage K, et al; SIGGAR Investigators. Computed tomographic colonography versus colonoscopy for investigation of patients with symptoms suggestive of colorectal cancer (SIGGAR): a multicentre randomised trial. Lancet. 2013 Apr 6;381(9873):1194-202.
http://www.ncbi.nlm.nih.gov/pubmed/23414650?tool=bestpractice.com
[126]Rockey RC, Paulson E, Niedzwiecki D, et al. Analysis of air contrast barium enema, computed tomographic colonography, and colonoscopy: prospective comparison. Lancet. 2005 Jan 22-28;365(9456):305-11.
http://www.ncbi.nlm.nih.gov/pubmed/15664225?tool=bestpractice.com
[127]Mulhall BP, Veerappan GR, Jackson JL. Meta-analysis: computed tomographic colonography. Ann Intern Med. 2005 Apr 19;142(8):635-50.
https://www.acpjournals.org/doi/full/10.7326/0003-4819-142-8-200504190-00013?rfr_dat=cr_pub++0pubmed&url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org
http://www.ncbi.nlm.nih.gov/pubmed/15838071?tool=bestpractice.com
CT colonography and optical colonoscopy are considered to be more sensitive tests than barium enema; patients appear to prefer CT colonography to double-contrast barium enema.[123]Halligan S, Wooldrage K, Dadswell E, et al; SIGGAR investigators. Computed tomographic colonography versus barium enema for diagnosis of colorectal cancer or large polyps in symptomatic patients (SIGGAR): a multicentre randomised trial. Lancet. 2013 Apr 6;381(9873):1185-93.
http://www.ncbi.nlm.nih.gov/pubmed/23414648?tool=bestpractice.com
[124]von Wagner C, Smith S, Halligan S, et al. Patient acceptability of CT colonography compared with double contrast barium enema: results from a multicentre randomised controlled trial of symptomatic patients. Eur Radiol. 2011 May 31;21(10):2046-55.
http://www.ncbi.nlm.nih.gov/pubmed/21626363?tool=bestpractice.com
[125]Rex DK, Rahmani EY, Haseman JH, et al. Relative sensitivity of colonoscopy and barium enema for detection of colorectal cancer in clinical practice. Gastroenterology. 1997 Jan;112(1):17-23.
http://www.ncbi.nlm.nih.gov/pubmed/8978337?tool=bestpractice.com
CT colonography can be used to complete colonic assessment when optical colonoscopy cannot be completed due to technical reasons such as a tortuous colon or stenosis. It can also be used to assess patients who are unwilling to undergo colonoscopy, who are not suitable candidates for colonoscopy, or for whom colonoscopy is contraindicated.
Imaging may need to be combined with flexible sigmoidoscopy if the sigmoid colon is not adequately visualised (e.g., in patients with severe diverticular disease).
Equivocal test results may need further investigation.
Further imaging and histology
Colon and rectal cancer should be confirmed by histology.[115]Vogel JD, Felder SI, Bhama AR, et al. The American Society of Colon and Rectal Surgeons clinical practice guidelines for the management of colon cancer. Dis Colon Rectum. 2022 Feb 1;65(2):148-77.
https://journals.lww.com/dcrjournal/Fulltext/2022/02000/The_American_Society_of_Colon_and_Rectal_Surgeons.7.aspx
http://www.ncbi.nlm.nih.gov/pubmed/34775402?tool=bestpractice.com
[128]Glynne-Jones L, Wyrwicz E, Tiret G, et al. Rectal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(suppl 4):iv22-iv40.
http://www.esmo.org/Guidelines/Gastrointestinal-Cancers/Rectal-Cancer
Once a diagnosis of colorectal cancer is made, further imaging is performed to stage the disease. Liver and chest imaging, usually with CT chest, abdomen, and pelvis, is necessary to detect metastases.[115]Vogel JD, Felder SI, Bhama AR, et al. The American Society of Colon and Rectal Surgeons clinical practice guidelines for the management of colon cancer. Dis Colon Rectum. 2022 Feb 1;65(2):148-77.
https://journals.lww.com/dcrjournal/Fulltext/2022/02000/The_American_Society_of_Colon_and_Rectal_Surgeons.7.aspx
http://www.ncbi.nlm.nih.gov/pubmed/34775402?tool=bestpractice.com
Magnetic resonance imaging (MRI) rectal cancer protocol (or transrectal endoscopic ultrasound if MRI is contraindicated) is necessary to provide a local (T and N) stage for rectal cancers, which is then used to help direct treatment choice.[129]National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: rectal cancer [internet publication].
https://www.nccn.org/professionals/physician_gls/default.aspx
MRI is the preferred modality for local staging because of its accuracy for determining both circumferential resection margin and T stage of the primary tumour.[130]Al-Sukhni E, Milot L, Fruitman M, et al. Diagnostic accuracy of MRI for assessment of T category, lymph node metastases, and circumferential resection margin involvement in patients with rectal cancer: a systematic review and meta-analysis. Ann Surg Oncol. 2012 Jul;19(7):2212-23.
http://www.ncbi.nlm.nih.gov/pubmed/22271205?tool=bestpractice.com
Imaging studies to consider
Indications for positron emission tomography (PET) scan include detection of extrahepatic metastases in patients thought to have liver-only metastatic disease in whom surgical metastasectomy is being considered.[131]Watson AJ, Lolohea S, Robertson GM, et al. The role of positron emission tomography in the management of recurrent colorectal cancer: a review. Dis Colon Rectum. 2007 Jan;50(1):102-14.
http://www.ncbi.nlm.nih.gov/pubmed/17115340?tool=bestpractice.com
[132]Zhang C, Chen Y, Xue H, et al. Diagnostic value of FDG-PET in recurrent colorectal carcinoma: a meta-analysis. Int J Cancer. 2009 Jan 1;124(1):167-73.
http://www.ncbi.nlm.nih.gov/pubmed/18844237?tool=bestpractice.com
[133]Facey K, Bradbury I, Laking G, et al. Overview of the clinical effectiveness of positron emission tomography imaging in selected cancers. Health Technol Assess. 2007 Oct;11(44):iii-iv, xi-267.
https://www.journalslibrary.nihr.ac.uk/hta/hta11440#/abstract
http://www.ncbi.nlm.nih.gov/pubmed/17999839?tool=bestpractice.com
However, one trial found that PET-CT did not result in frequent change to surgical management compared with CT alone in patients with potentially resectable liver metastases.[134]Moulton CA, Gu CS, Law CH, et al. Effect of PET before liver resection on surgical management for colorectal adenocarcinoma metastases: a randomized clinical trial. JAMA. 2014 May 14;311(18):1863-9.
https://jamanetwork.com/journals/jama/fullarticle/1869209
http://www.ncbi.nlm.nih.gov/pubmed/24825641?tool=bestpractice.com
PET may help to identify recurrence in patients in whom this is suspected on the basis of symptoms or a rising carcinoembryonic antigen, but in whom the diagnostic work-up is negative.[135]Flamen P, Hoekstra OS, Homans F, et al. Unexplained rising carcinoembryonic antigen (CEA) in the postoperative surveillance of colorectal cancer: the utility of positron emission tomography (PET). Eur J Cancer. 2001 May;37(7):862-9.
http://www.ncbi.nlm.nih.gov/pubmed/11313174?tool=bestpractice.com
[136]Royal College of Radiologists, Royal College of Physicians. Evidence-based indications for the use of PET-CT in the United Kingdom 2022 [internet publication].
https://www.rcr.ac.uk/publication/evidence-based-indications-use-pet-ct-united-kingdom-2022
[137]Yu T, Meng N, Chi D, et al. Diagnostic value of (18)F-FDG PET/CT in detecting local recurrent colorectal cancer: a pooled analysis of 26 individual studies. Cell Biochem Biophys. 2015 Jun;72(2):443-51.
http://www.ncbi.nlm.nih.gov/pubmed/25737131?tool=bestpractice.com
Laboratory investigations
Routine full blood count, liver biochemistry, bone profile, and renal function are recommended baseline tests.
Quantitative faecal immunochemical test (FIT)
Small amounts of blood in faeces, which indicates possible colorectal cancer, is detected by FIT.[111]National Institute for Health and Care Excellence. Suspected cancer: recognition and referral. Aug 2023 [internet publication].
https://www.nice.org.uk/guidance/ng12
[138]National Institute for Health and Care Excellence. Quantitative faecal immunochemical testing to guide colorectal cancer pathway referral in primary care. Aug 2023 [internet publication].
https://www.nice.org.uk/guidance/dg56
The UK guidelines recommend offering FIT in primary care settings to detect people likely to have colorectal cancer, so as to prioritise them for referral to secondary care.[111]National Institute for Health and Care Excellence. Suspected cancer: recognition and referral. Aug 2023 [internet publication].
https://www.nice.org.uk/guidance/ng12
[138]National Institute for Health and Care Excellence. Quantitative faecal immunochemical testing to guide colorectal cancer pathway referral in primary care. Aug 2023 [internet publication].
https://www.nice.org.uk/guidance/dg56
FIT Symptomatic
Opens in new window Quantitative FIT using HM‑JACKarc or OC‑Sensor to guide referral for suspected colorectal cancer is recommended in adults:
with an abdominal mass, or
with a change in bowel habit, or
with iron-deficiency anaemia, or
aged ≥40 years with unexplained weight loss and abdominal pain, or
aged <50 years with rectal bleeding and either unexplained abdominal pain or unexplained weight loss, or
aged ≥50 years with unexplained rectal bleeding, abdominal pain, or weight loss, or
aged ≥60 years with anaemia in the absence of iron-deficiency.
The UK guidelines recommend FIT in people having previous negative FIT results. FIT should not be offered to people with a rectal mass, an unexplained anal mass, or unexplained anal ulceration before referral is considered.[111]National Institute for Health and Care Excellence. Suspected cancer: recognition and referral. Aug 2023 [internet publication].
https://www.nice.org.uk/guidance/ng12
[138]National Institute for Health and Care Excellence. Quantitative faecal immunochemical testing to guide colorectal cancer pathway referral in primary care. Aug 2023 [internet publication].
https://www.nice.org.uk/guidance/dg56
If the FIT result is ≥10 micrograms of haemoglobin/g of faeces, refer patients urgently (schedule an appointment within 2 weeks). If colorectal cancer is suspected, give safety-netting advice and do not delay referral, even if people do not return a faecal sample or have a FIT result of <10 micrograms of haemoglobin/g. Based on FIT results, investigations such as colonoscopy can be avoided in people who are less likely to have colorectal cancer, thus making the resources available to those who need them the most.[111]National Institute for Health and Care Excellence. Suspected cancer: recognition and referral. Aug 2023 [internet publication].
https://www.nice.org.uk/guidance/ng12
[138]National Institute for Health and Care Excellence. Quantitative faecal immunochemical testing to guide colorectal cancer pathway referral in primary care. Aug 2023 [internet publication].
https://www.nice.org.uk/guidance/dg56
Genetic tests
US and UK national guidelines recommend that all patients who are diagnosed with colon or rectal cancer should be tested for Lynch syndrome.[129]National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: rectal cancer [internet publication].
https://www.nccn.org/professionals/physician_gls/default.aspx
[139]National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: colon cancer [internet publication].
https://www.nccn.org/professionals/physician_gls/default.aspx
[140]National Institute for Health and Care Excellence. Colorectal cancer. Quality standard (QS20). Feb 2022 [internet publication].
https://www.nice.org.uk/guidance/qs20/chapter/Quality-statements
Test results may inform choice of systemic therapy, cancer risk reduction strategies in other sites, and testing of family members.
All patients with metastatic colorectal cancer should have tumour genotyped for RAS (KRAS and NRAS) and BRAF mutations individually or as part of a next-generation sequencing panel.[129]National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: rectal cancer [internet publication].
https://www.nccn.org/professionals/physician_gls/default.aspx
[139]National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: colon cancer [internet publication].
https://www.nccn.org/professionals/physician_gls/default.aspx
Testing should be performed only in certified laboratories.
Blood-based colorectal cancer screening
Blood-based tests (also known as liquid biopsy) have been developed in recent times to aid colorectal cancer screening.[141]Lieberman DA, AGA CRC Workshop Panel. Commentary: liquid biopsy for average-risk colorectal cancer screening. Clin Gastroenterol Hepatol. 2024 Jun;22(6):1160-4.e1.
http://www.ncbi.nlm.nih.gov/pubmed/38552672?tool=bestpractice.com
[142]Chung DC, Gray DM 2nd, Singh H, et al. A cell-free DNA blood-based test for colorectal cancer screening. N Engl J Med. 2024 Mar 14;390(11):973-83.
https://www.nejm.org/doi/10.1056/NEJMoa2304714
http://www.ncbi.nlm.nih.gov/pubmed/38477985?tool=bestpractice.com
Studies comparing blood-based tests with established diagnostic tests such as FIT found that blood-based tests were less sensitive and expensive.[143]Ladabaum U, Mannalithara A, Weng Y, et al. Comparative effectiveness and cost-effectiveness of colorectal cancer screening with blood-based biomarkers (liquid biopsy) vs fecal tests or colonoscopy. Gastroenterology. 2024 Jul;167(2):378-91.
http://www.ncbi.nlm.nih.gov/pubmed/38552670?tool=bestpractice.com
[144]van den Puttelaar R, Nascimento de Lima P, Knudsen AB, et al. Effectiveness and Cost-Effectiveness of Colorectal Cancer Screening With a Blood Test That Meets the Centers for Medicare & Medicaid Services coverage decision. Gastroenterology. 2024 Jul;167(2):368-77.
https://www.gastrojournal.org/article/S0016-5085(24)00174-4/fulltext
http://www.ncbi.nlm.nih.gov/pubmed/38552671?tool=bestpractice.com
Blood-based testing may be performed over no screening but should not replace the existing tests. The Septin 9 blood test is the only FDA-approved test for serum colorectal cancer screening in adults who refuse testing with other tests endorsed by the US Preventive Services Task Force.[145]Burke CA, Lieberman D, Feuerstein JD. AGA Clinical practice update on approach to the use of noninvasive colorectal cancer screening options: commentary. Gastroenterology. 2022 Mar;162(3):952-6.
https://www.gastrojournal.org/article/S0016-5085(21)03732-X/fulltext
http://www.ncbi.nlm.nih.gov/pubmed/35094786?tool=bestpractice.com
None of the guidelines endorse this test for routine colorectal cancer screening.[145]Burke CA, Lieberman D, Feuerstein JD. AGA Clinical practice update on approach to the use of noninvasive colorectal cancer screening options: commentary. Gastroenterology. 2022 Mar;162(3):952-6.
https://www.gastrojournal.org/article/S0016-5085(21)03732-X/fulltext
http://www.ncbi.nlm.nih.gov/pubmed/35094786?tool=bestpractice.com